Clinical outcomes of Atezolizumab Therapy for Previously-Treated Advanced-Stage Non-Small Cell Lung Cancer: A Real-World Study in Taiwan

Immune checkpoint inhibitors (ICIs) are the standard treatment for non-small-cell lung cancer (NSCLC). We assessed the clinical prognostic factors in NSCLC patients receiving atezolizumab as a second- or later-line (2L+) treatment. Data were retrospectively collected for NSCLC patients treated with...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Shang-Gin, Chiang, Chi-Lu, Wang, Chin-Chou, Hung, Jen-Yu, Hsia, Te-Chun, Kuo, Chih-Hsi, Shih, Jin-Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9330461/
https://www.ncbi.nlm.nih.gov/pubmed/35912016
http://dx.doi.org/10.7150/jca.74617

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9330461/
https://www.ncbi.nlm.nih.gov/pubmed/35912016
http://dx.doi.org/10.7150/jca.74617

Ejemplares similares